Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization

Bermudez, Adriana; Reyes, Claudia; Guzmán, Fanny; Vanegas, Magnolia; Rosas, Jaiver; Amador, Roberto; Rodríguez, Raul; Patarroyo, Manuel A.; Patarroyo, Manuel Elkin

doi:https://doi.org/10.1016/j.vaccine.2007.03.016

Ítem

Solo Metadatos

Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization

https://repository.urosario.edu.co/handle/10336/27007
https://doi.org/10.1016/j.vaccine.2007.03.016

Autores

Bermudez, Adriana

Reyes, Claudia

Guzmán, Fanny

Vanegas, Magnolia

Rosas, Jaiver

Amador, Roberto

Rodríguez, Raul

Patarroyo, Manuel A.

Patarroyo, Manuel Elkin

Fecha

2007-05-30

Editor

The Japanese Society for Vaccinology
Elsevier

Buscar en:

Métricas alternativas

Abstract

The SPf66 synthetic malaria vaccine, developed and obtained almost 2 decades ago, represents the first approach towards developing a multi-antigenic, multi-stage synthetic malarial vaccine composed of subunits derived from different Plasmodium falciparum stage proteins. It is shown here that batches 03, 04, 05, 06, 07, 08, 09, 10, 11, 12, 13, 14, 15 and 16 produced from a few milligrams to kilogram amounts and used in assays on monkeys and humans showed high reproducibility in physicochemical analysis. 1H NMR two-dimensional studies also revealed high similarity, even in non-oxidized batches. Reproducibility was also high, especially in preclinical studies carried out on Aotus, clinical trials Phase I, IIa and IIb and field-studies carried out in La Tola, Rio Rosario (Colombia), Majadas (Venezuela), La Te (Ecuador), Ifakara (Tanzania) in which there was high antibody titer production, having similar population distribution when done with different batches.